Used as a key intermediate in the synthesis of epidermal growth factor receptor (EGFR) inhibitors, particularly in targeted cancer therapies. Its structure enables selective binding to tyrosine kinase domains, making it valuable in the development of anticancer agents. Commonly employed in pharmaceutical research for designing drugs against non-small cell lung cancer and other solid tumors. Also utilized in structure-activity relationship (SAR) studies to optimize potency and selectivity of quinazoline-based kinase inhibitors.